All the results together show the complexity of the effects of a class I HDAC‐specific PROTAC on DLBCL cells, which are likely to depend both on the inhibition of HDAC expression and activity, and other unrelated functions. The gene discussed is HDAC9; the disease is diffuse large B-cell lymphoma.